Boston Scientific: 3 Key Takeaways for Long-Term Investors

Boston Scientific reported that an eight-day cyber incident and product line headwinds will flatten sales and earnings growth through 2027. The company is implementing a $500 million cost-cutting restructuring program while advancing new product pipelines targeting $25 billion in market opportunities by 2030. Management expects stabilization in 2027 and reaccelerated growth beginning in 2028.